CTLA4 and neoplasm: Here, we showed that the combination of ICB with anti-PD1 or anti-CTLA4 antibodies with specific anti-tumor antibodies (TA99) results in an increased efficacy against B16 subcutaneous and lung melanomas, in agreement with previous reports showing that therapy with anti-HER2 antibodies synergizes with immune checkpoint blockade with anti-PD1 in mouse models of breast cancer [31].